RI2 Stock Chart & Stats
€41.49
-€0.54(-1.63%)
At close: 4:00 PM EDT
€41.49
-€0.54(-1.63%)
Day’s Range― - ―
52-Week Range€21.20 - €44.47
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€849.97M
Enterprise Value€710.20M
Total Cash (Recent Filing)€95.33M
Total Debt (Recent Filing)€39.95M
Price to Earnings (P/E)2.9
Beta0.96
Next Earnings
Nov 10, 2026EPS Estimate
0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)17.67
Shares Outstanding18,679,865
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.97
Price to Sales (P/S)2.62
P/FCF Ratio10.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€58.43Price Target Upside40.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)3.05
Revenue Forecast (FY)€272.21M
Bulls Say, Bears Say
Bulls Say
Commercial Product GrowthGrowth across the marketed portfolio indicates improving commercial traction rather than reliance on a single product. TAVALISSE’s record quarter and REZLIDHIA’s faster expansion can support recurring revenue, broader customer reach, and a stronger platform for future portfolio investment.
Profitability And Cash GenerationPositive operating and free cash flow, combined with very high gross margins, gives Rigel internal resources to fund development and commercialization. This marks a material improvement from earlier cash-burning periods and strengthens financial flexibility over the coming quarters.
VEPPANU Commercial OpportunityThe differentiated clinical results and sizable addressable population provide a credible basis for adding a major oncology revenue stream. If launch execution converts the efficacy profile into adoption, VEPPANU could materially broaden Rigel’s commercial scale and product mix.
Bears Say
Reduced LiquidityThe substantial reduction in cash reserves lowers liquidity headroom as Rigel funds launches, research, and development commitments. Less cash flexibility can increase dependence on operating performance or external financing if spending remains elevated or commercial returns take longer.
VEPPANU Financial ObligationsVEPPANU offers growth potential but its upfront, milestone, royalty, and development commitments could absorb a meaningful portion of future economics. These obligations may pressure margins and cash generation, particularly if launch adoption or regulatory progress is slower than expected.
Early-stage Pipeline UncertaintyR289’s preliminary efficacy signal is based on a small patient dataset, so its durability and broader applicability remain unproven. Until larger cohorts confirm the response and support later development, the program provides potential but cannot yet reliably offset commercial or pipeline risk.
Rigel News
RI2 FAQ
What was Rigel’s price range in the past 12 months?
Rigel lowest stock price was €21.20 and its highest was €44.47 in the past 12 months.
What is Rigel’s market cap?
Rigel’s market cap is €849.97M.
When is Rigel’s upcoming earnings report date?
Rigel’s upcoming earnings report date is Nov 10, 2026 which is in 11 days.
How were Rigel’s earnings last quarter?
Rigel released its earnings results on Aug 04, 2026. The company reported €0.786 earnings per share for the quarter, beating the consensus estimate of €0.079 by €0.707.
Is Rigel overvalued?
According to Wall Street analysts Rigel’s price is currently Undervalued.
Does Rigel pay dividends?
Rigel does not currently pay dividends.
What is Rigel’s EPS estimate?
Rigel’s EPS estimate is 0.82.
How many shares outstanding does Rigel have?
Rigel has 18,679,865 shares outstanding.
What happened to Rigel’s price movement after its last earnings report?
Rigel reported an EPS of €0.786 in its last earnings report, beating expectations of €0.079. Following the earnings report the stock price went up 7.593%.
Which hedge fund is a major shareholder of Rigel?
Currently, no hedge funds are holding shares in DE:RI2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rigel Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€58.43 (40.83% Upside)
€58.43 (40.83% Upside)
Blogger Sentiment
Bullish
DE:RI2 Sentiment 73%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.89%
12-Months-Change
Fundamentals
Return on Equity
96.49%
Trailing 12-Months
Asset Growth
152.04%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Rigel
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
RI2 Company Deck
RI2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple meaningful commercial and pipeline achievements—most notably the in‑license and imminent launch of VEPPANU with strong phase III efficacy, ongoing commercial revenue growth (14% product sales growth, record TAVALISSE quarter, 27% REZLIDHIA growth), and promising early R289 data with regulatory incentives. These positives are tempered by lower year‑over‑year net income (partly due to one‑time prior‑year items), a substantial decline in cash reserves (~38.5%), higher operating expenses (+~35.7%), modest decline in GAVRETO sales, and significant upfront/milestone/royalty obligations tied to VEPPANU that may pressure margins and cash flow. Overall, the company communicated confident launch readiness and an optimistic strategic trajectory but with near‑term financial and execution risks to monitor.View all DE:RI2 earnings summariesRI2 Stock 12 Month Forecast
Average Price Target
€58.43
▲(40.83% Upside)